Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Crohn's disease
Last updated December 19, 2025
Myfembree (relugolix, estradiol, and norethindrone acetate)
Status:
Concluded with an LOI
Manufacturer:
Knight Therapeutics Inc.
Indication:
Management of heavy menstrual bleeding associated with uterine fibroids
Last updated December 12, 2025
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Last updated December 11, 2025
Omnipod 5 (Automated Insulin Delivery System)
Status:
Concluded with an LOI
Manufacturer:
Insulet Canada Corporation
Indication:
Patients with Type 1 Diabetes aged 2 years and old
Last updated December 11, 2025
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated December 10, 2025
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Last updated December 3, 2025
Status:
Negotiations were not pursued (Manufacturer withdrew from negotiation)
Manufacturer:
Amgen Canada Inc.
Indication:
Advanced non-small cell lung cancer, KRAS G12C-mutated
Last updated December 3, 2025
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Last updated December 1, 2025
Status:
Concluded without agreement (Manufacturer declined negotiation)
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
Last updated December 1, 2025
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.
Last updated November 28, 2025